Monday, 11 February 2013

Tysabri to become potential ‘first line’ therapy for MS

Source MS Society:

The manufacturers of Tysabri have applied to the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the USA for the approval of Tysabri as a first-line treatment for people with relapsing remitting MS, who have tested negative for antibodies to the JC virus.

Read more here!